Abstract
l-3, 4-Dihydroxyphenylalanine ( l-dopa) has been widely used for the treatment of Parkinson's disease (PD), but its pharmacokinetics in the striatum have hardly been investigated, especially in primates. In this study, we examined the concentration of l-dopa in plasma and in the extracellular fluid (ECF) of the striatum in common marmosets using microdialysis and high-performance liquid chromatography (HPLC) with electrochemical detection. With a clinically therapeutic dosage of l-dopa/benserazide (20/5 mg/kg, p.o.), the t max of l-dopa was 30 min in plasma and 60–90 min in ECF of striatum. Mean C max was 20.3 μM in plasma and 442.9 nM in ECF of striatum, which is about 2.2% of that in plasma. The l-dopa concentration in ECF is much lower than those previously applied during in vivo studies for l-dopa toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
